JP2017518258A5 - - Google Patents

Download PDF

Info

Publication number
JP2017518258A5
JP2017518258A5 JP2016557031A JP2016557031A JP2017518258A5 JP 2017518258 A5 JP2017518258 A5 JP 2017518258A5 JP 2016557031 A JP2016557031 A JP 2016557031A JP 2016557031 A JP2016557031 A JP 2016557031A JP 2017518258 A5 JP2017518258 A5 JP 2017518258A5
Authority
JP
Japan
Prior art keywords
antibody
seq
humanized antibody
mcam
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016557031A
Other languages
English (en)
Japanese (ja)
Other versions
JP6728053B2 (ja
JP2017518258A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2015/051786 external-priority patent/WO2015136469A1/en
Publication of JP2017518258A publication Critical patent/JP2017518258A/ja
Publication of JP2017518258A5 publication Critical patent/JP2017518258A5/ja
Application granted granted Critical
Publication of JP6728053B2 publication Critical patent/JP6728053B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016557031A 2014-03-12 2015-03-12 抗ｍｃａｍ抗体及び関連する使用方法 Expired - Fee Related JP6728053B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461952123P 2014-03-12 2014-03-12
US61/952,123 2014-03-12
US201462023698P 2014-07-11 2014-07-11
US62/023,698 2014-07-11
US201462068438P 2014-10-24 2014-10-24
US62/068,438 2014-10-24
PCT/IB2015/051786 WO2015136469A1 (en) 2014-03-12 2015-03-12 Anti-mcam antibodies and associated methods of use

Publications (3)

Publication Number Publication Date
JP2017518258A JP2017518258A (ja) 2017-07-06
JP2017518258A5 true JP2017518258A5 (cg-RX-API-DMAC7.html) 2018-04-19
JP6728053B2 JP6728053B2 (ja) 2020-07-22

Family

ID=52823723

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016557031A Expired - Fee Related JP6728053B2 (ja) 2014-03-12 2015-03-12 抗ｍｃａｍ抗体及び関連する使用方法

Country Status (9)

Country Link
US (2) US10407506B2 (cg-RX-API-DMAC7.html)
EP (1) EP3116911B8 (cg-RX-API-DMAC7.html)
JP (1) JP6728053B2 (cg-RX-API-DMAC7.html)
KR (1) KR20160127825A (cg-RX-API-DMAC7.html)
CA (1) CA2938946A1 (cg-RX-API-DMAC7.html)
DK (1) DK3116911T3 (cg-RX-API-DMAC7.html)
ES (1) ES2744526T3 (cg-RX-API-DMAC7.html)
PT (1) PT3116911T (cg-RX-API-DMAC7.html)
WO (1) WO2015136469A1 (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI660972B (zh) 2012-09-10 2019-06-01 愛爾蘭商尼歐托普生物科學公司 抗ｍｃａｍ抗體及相關使用方法
US10407506B2 (en) 2014-03-12 2019-09-10 Prothena Biosciences Limited Anti-MCAM antibodies and associated methods of use
JP2017514458A (ja) 2014-03-12 2017-06-08 プロセナ バイオサイエンシーズ リミテッド Ｌｇ４−５に対して特異的な抗−ラミニン４抗体
WO2017046774A2 (en) * 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017149513A1 (en) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2017153953A1 (en) * 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017153955A1 (en) * 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
EP4235175A3 (en) * 2017-05-05 2023-10-11 National University of Singapore Methods for culturing human keratinocytes
AU2018291082B2 (en) * 2017-06-27 2025-05-29 Neuracle Science Co., Ltd. Anti-FAM19A5 antibodies and uses thereof
CN119607195A (zh) 2018-04-24 2025-03-14 纽洛可科学有限公司 抗序列相似家族19成员a5的抗体在治疗神经性疼痛中的用途
JP7578289B2 (ja) * 2018-12-21 2024-11-06 マルチチュード インコーポレーテッド Ｍｕｃ１８に特異的な抗体
JP7575102B2 (ja) 2018-12-21 2024-10-29 マルチチュード インコーポレーテッド Ｍｕｃ１８に特異的な抗体
US20220308056A1 (en) * 2021-02-05 2022-09-29 Omeros Corporation Biomarker for assessing the risk of developing acute covid-19 and post-acute covid-19
EP4463135A2 (en) 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024079074A1 (en) * 2022-10-10 2024-04-18 Universite D'aix Marseille ANTI-sCD146 ANTIBODIES AND USES THEREOF
WO2024081820A1 (en) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
AU2024274792A1 (en) 2023-05-23 2025-10-23 Sana Biotechnology, Inc. Tandem fusogens and related lipid particles
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
CN117069848B (zh) * 2023-08-02 2025-02-28 武汉爱博泰克生物科技有限公司 抗人cd146兔单克隆抗体及其应用
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
DE69230142T2 (de) 1991-05-15 2000-03-09 Cambridge Antibody Technology Ltd. Verfahren zur herstellung von spezifischen bindungspaargliedern
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5877218A (en) 1994-01-10 1999-03-02 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
WO1998040100A1 (en) 1997-03-10 1998-09-17 Ottawa Civic Loeb Research Institute USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
AU757961B2 (en) 1998-09-30 2003-03-13 Sankyo Company Limited Anti-Fas antibodies
CA2625839A1 (en) 1999-02-05 2000-08-10 Samsung Electronics Co., Ltd. Image texture retrieving method and apparatus thereof
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US7192931B2 (en) 2000-10-12 2007-03-20 Neuren Pharmaceuticals Ltd. Treatment of demyelinating diseases
US20030068319A1 (en) 2001-03-23 2003-04-10 Menashe Bar-Eli Methods for inhibition of angiogenesis, tumor growth and metastasis by fully human anti-IL8 and anti-MUC18 in diverse types of tumors
IL166244A0 (en) 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
TWI334439B (en) 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
ES2307824T3 (es) * 2001-12-28 2008-12-01 Amgen Fremont Inc. Uso de anticuerpos contra el antigeno muc18.
EP1467756A4 (en) 2001-12-28 2007-03-21 Abgenix Inc METHODS OF USING ANTI-MUC18 ANTIBODIES
AU2002361886A1 (en) 2001-12-28 2003-07-24 Abgenix, Inc. Antibodies against the muc18 antigen
US7456260B2 (en) * 2002-06-17 2008-11-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Humanized antibody
EP1382615A1 (en) * 2002-07-15 2004-01-21 Xerion Pharmaceuticals AG MCAM inhibitors
EP1567652B1 (de) 2002-11-29 2007-08-22 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Neue neomycin-phosphotransferase-gene und verfahren zur selektion von hochproduzierenden rekombinanten zellen
JP2007521249A (ja) 2003-01-24 2007-08-02 エラン ファーマシューティカルズ，インコーポレイテッド 脱髄疾患および麻痺のための組成物ならびに再有髄化剤を投与することによるそれらの治療
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
ES2415665T3 (es) * 2004-06-21 2013-07-26 Proteome Sciences Plc Procedimientos de cribado usando c-abl, fyn y sky en combinación con la proteína tau
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
ATE433110T1 (de) 2004-11-10 2009-06-15 Boehringer Ingelheim Pharma Verwendung von durchflusszytometrischer analyse zur optimierung von zellbankingstrategien für cho-zellen
WO2007058725A2 (en) 2005-10-12 2007-05-24 The Regents Of The University Of California Engineered antibody fragment that irreversibly binds an antigen
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
EP2609932B1 (en) 2006-12-01 2022-02-02 Seagen Inc. Variant target binding agents and uses thereof
DK2126093T3 (da) 2007-03-02 2013-01-07 Boehringer Ingelheim Pharma Forbedring af proteinfremstilling
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
WO2009028663A1 (ja) 2007-08-30 2009-03-05 Kyowa Hakko Kirin Co., Ltd. 抗Claudin-3抗体
US20120047586A9 (en) 2007-10-24 2012-02-23 Otsuka Chemical Co., Ltd Polypeptide having enhanced effector function
EP2500362A3 (en) 2007-11-13 2012-10-24 Teva Biopharmaceuticals USA, Inc. Humanized antibodies against TL1A
ES2511844T3 (es) 2007-12-21 2014-10-23 F. Hoffmann-La Roche Ag Formulación de anticuerpo
AR070141A1 (es) 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
US8293468B2 (en) 2009-06-10 2012-10-23 Centre Hospitalier De L'université De Montréal MCAM modulation and uses thereof
WO2011100477A2 (en) 2010-02-10 2011-08-18 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
BR112012021941A2 (pt) 2010-03-02 2022-02-01 Abbvie Inc Proteínas terapêuticas de ligação a dll4
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
EP2718327A1 (en) 2011-06-06 2014-04-16 Neotope Biosciences Limited Mcam antagonists and methods of treatment
ES2732243T3 (es) 2012-02-16 2019-11-21 Santarus Inc Composiciones farmacéuticas de anticuerpos ANTI-VLA1 (CD49A)
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
TWI660972B (zh) 2012-09-10 2019-06-01 愛爾蘭商尼歐托普生物科學公司 抗ｍｃａｍ抗體及相關使用方法
SG10201803178UA (en) 2013-10-24 2018-05-30 Astrazeneca Ab Stable, aqueous antibody formulations
WO2015136570A1 (ja) 2014-03-11 2015-09-17 パナソニック液晶ディスプレイ株式会社 表示装置及びその駆動方法
US20170129954A1 (en) 2014-03-12 2017-05-11 Prothena Biosciences Limited Use of Anti-MCAM Antibodies for Treatment or Prophylaxis of Giant Cell Arteritis, Polymyalgia Rheumatica or Takayasus Arteritis
JP2017514458A (ja) 2014-03-12 2017-06-08 プロセナ バイオサイエンシーズ リミテッド Ｌｇ４−５に対して特異的な抗−ラミニン４抗体
US10407506B2 (en) 2014-03-12 2019-09-10 Prothena Biosciences Limited Anti-MCAM antibodies and associated methods of use
TW201623331A (zh) 2014-03-12 2016-07-01 普羅帝納生物科學公司 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
JP2017512772A (ja) 2014-03-12 2017-05-25 プロセナ バイオサイエンシーズ リミテッド Ｌｇ１〜３に特異的な抗ラミニン４抗体
US20170101470A1 (en) 2014-03-12 2017-04-13 Prothena Biosciences Limited Use of Anti-MCAM Antibodies for Treatment or Prophylaxis of Giant Cell Arteritis, Polymyalgia Rheumatica or Takayasus Arteritis
KR20170052526A (ko) 2014-03-13 2017-05-12 프로테나 바이오사이언시즈 리미티드 다발성 경화증에 대한 병용 치료
WO2017046776A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017046774A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017149513A1 (en) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2018223140A1 (en) 2017-06-02 2018-12-06 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use

Similar Documents

Publication Publication Date Title
JP2017518258A5 (cg-RX-API-DMAC7.html)
JP2015533795A5 (cg-RX-API-DMAC7.html)
HRP20240719T1 (hr) Kimerna i humanizirana monoklonska protutijela protiv ljudskog ctla4 i njihova upotreba
WO2016191643A4 (en) Tigit-binding agents and uses thereof
JP2016512551A5 (cg-RX-API-DMAC7.html)
PH12018550179A1 (en) Anti-pd-1 antibodies, method for producing same and method for using same
JP2017510567A5 (cg-RX-API-DMAC7.html)
MY175878A (en) Anti-il-17 antibodies, a method for producing and using thereof
EA202091590A1 (ru) Антитела против pd-l1 и варианты их применения
JOP20190248A1 (ar) بروتينات ربط مولد ضد trem2 واستخداماته
RU2016100892A (ru) Антитела против tweakr и их применение
PH12018501220A1 (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
EA201790342A1 (ru) Антитела к trem2 и способы их применения
PE20181336A1 (es) Anticuerpos que se unen a interleucina 8 (il-8) y sus usos
PE20240218A1 (es) Anticuerpos madurados por afinidad y humanizados para fcrh5
PE20181363A1 (es) Variantes optimizadas de anticuerpos anti-vegf
MX2020008736A (es) Formulaciones de anticuerpos b7-h4.
EA201891732A1 (ru) Биспецифичные связывающие белки для pd-l1 и kdr
EA202090401A1 (ru) Анти-tim-3 антитела и их применение
WO2015187521A3 (en) Anti-blys antibodies
FI3515947T3 (fi) Uudet tekijän XI vasta-aineet ja niiden käyttökohteet
EA202190807A1 (ru) Антитела к синуклеину
PH12015501632A1 (en) Humanized anti-hmgbi antibody or antigen-binding fragment thereof
MX2019015914A (es) Anticuerpos quiméricos para el tratamiento de enfermedades por deposición de amiloide.
WO2018071504A3 (en) Methods of treating diseases with il-23a antibody